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Nothing in life is to be feared, it is only to be understood. Now is 
the time to understand more, so that we may fear less.  
― Marie Curie 
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SUMMARY 
 
Neuroblastoma (NB) is a pediatric cancer of the developing sympathetic nervous 
system that accounts for more than 7% of all childhood cancers. It is the most common 
extracranial solid tumor diagnosed during infancy and is responsible for around 10 to 12% 
of childhood cancer-related deaths. Although most NB tumors arise sporadically, around 1 
to 2% of the cases are inherited in an autosomal dominant manner.  Anaplastic lymphoma 
kinase (ALK) is a cell-membrane associated tyrosine kinase receptor, preferentially 
expressed in the central and peripheral nervous system. Relatively recent findings have 
suggested that the ALK gene may be activated by genomic rearrangements or specific point 
mutations targeting the tyrosine kinase domain (TKD), thereby contributing to tumor 
development, and that NB harboring this ALK alterations might be sensitive to ALK 
inhibitors. Additionally, ALK germline mutations explain a large proportion of hereditary NB, 
being present in approximately half of hereditary cases.  
In the present study, we aimed to search for ALK fusion genes, to compare the 
pattern of amplification of the ALK and MYCN genes, to identify somatic and germline ALK 
TKD point mutations and to relate the ALK alterations with clinical outcome in NB patients. 
We therefore performed fluorescence in situ hybridization (FISH) in 41 cell suspension 
tumor samples and Sanger sequencing in 29 fresh-frozen tumor samples from NB patients 
treated at IPO-Porto from 2003 to 2016 and tested for MYCN amplification at the 
Department of Genetics of that institution. Whenever possible, normal tissue was analyzed 
from patients presenting mutations in tumor samples. 
Of the 41 patients assessed by FISH, no translocation or inversion were found, but 
aberrant copy number of the ALK gene was observed in 19 cases (46.3%). This included 
ALK amplification in one of 41 (2.4%), ALK gain in 13 of 41 (31.7%), and ALK 
loss/imbalance in five of 41 (12.2%), changes that in general are associated with more 
advanced clinical stages and worse outcomes. Additionally, polysomy of chromosome 2 
was observed in 15 cases (36.6%), which is an indicator of a better outcome in patients 
without other adverse prognostic features. Synchronic MYCN and ALK aberrations 
accounted for 17 of 41 (41%) tumors. Moreover, we found four different ALK TKD mutations 
in five of 29 tumors tested by Sanger sequencing, namely, the F1174L, R1192P, F1174I, 
and R1275Q mutations. Of these, the mutations R1192P and R1275Q were found in the 
germline of two patients, being the most frequent ALK germline mutations described in 
hereditary NB.  
We conclude that ALK alterations are a frequent event in NB patients, either by 
cytogenetic events or point mutations, and that these alterations could be a predictive and 
 xxviii 
 
prognostic biomarker, which can also be a potential therapeutic target in a subset of 
patients. We also show the importance of understanding which ALK mutations are more 
likely to be associated with inherited predisposition to NB tumors, which can help direct 
appropriate screening in families carrying ALK germline mutations.  
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RESUMO 
 
O neuroblastoma (NB) é um cancro pediátrico que surge durante o desenvolvimento 
do sistema nervoso simpático e que representa mais de 7% de todos os cancros na 
infância. É o tumor sólido extracraniano mais frequentemente diagnosticado na infância e 
é responsável por cerca de 10 a 12% da mortalidade por cancro em crianças. Embora a 
maioria dos NBs sejam esporádicos, cerca de 1 a 2% dos casos são hereditários, com 
transmissão autossómica dominante. O gene ALK codifica um recetor tirosina quinase 
transmembranar, que é preferencialmente expresso no sistema nervoso central e 
periférico. Estudos relativamente recentes sugerem que o gene ALK pode ser ativado 
devido à ocorrência de rearranjos cromossómicos ou mutações pontuais no domínio 
tirosina quinase, contribuindo para o desenvolvimento tumoral. Tumores que apresentam 
alterações no gene ALK podem responder a inibidores do ALK. Além disso, mutações 
germinativas no gene ALK são responsáveis pela maioria dos tumores hereditários, 
estando presente em aproximadamente metade dos casos. 
O presente estudo teve como principais objetivos pesquisar genes de fusão 
envolvendo o gene ALK; comparar o padrão de amplificação dos genes ALK e MYCN; 
identificar mutações pontuais somáticas e germinativas no domínio tirosina quinase do 
gene; e, ainda, relacionar as alterações encontradas no gene ALK com dados clinico-
patológicos dos pacientes com NB. Foi utilizada a técnica de FISH em 41 amostras de 
células tumorais em suspensão e sequenciação de Sanger em 29 amostras de tumores 
frescos congelados de pacientes com NB tratados no IPO-Porto de 2003 a 2016 e testados 
para amplificação do gene MYCN no Serviço de Genética daquela instituição. Sempre que 
possível, foi efetuada a análise de tecido normal dos pacientes com mutação no gene ALK 
na amostra tumoral. 
Dos 41 pacientes avaliados por FISH, não foram encontrados casos com 
translocação ou inversão, mas foi observado um número de cópias aberrante do gene ALK 
em 19 casos (46,3%). Destes, foi identificada amplificação em um caso (2,4%), ganho do 
ALK em 13 casos (31,7%) e perda/desequilíbrio do ALK em cinco casos (12,2%), 
alterações que em geral estão associadas a estádios clínicos mais avançados e a pior 
prognóstico. Adicionalmente, foi observada polissomia do cromossomo 2 em 15 casos 
(36,6%), que está associada a um melhor prognóstico em pacientes sem outras 
características de mau prognóstico. A co-ocorrência de alterações nos genes MYCN e ALK 
foi detetada em 17 casos (41%). Além disso, encontrámos quatro mutações no domínio 
tirosina quinase do gene ALK em cinco dos 29 tumores analisados por sequenciação de 
Sanger, nomeadamente, as mutações F1174L, R1192P, F1174I e R1275Q. Destas, as 
 xxxii 
 
mutações R1192P e R1275Q foram encontradas na linha germinativa de dois pacientes, 
sendo as mais frequentemente reportadas no NB hereditário. 
Concluímos assim que alterações no gene ALK são um evento frequente em 
pacientes com NB, quer seja devido a eventos citogenéticos ou à ocorrência de mutações 
pontuais. Estas alterações poderão ser utilizadas como biomarcador preditivo e de 
prognóstico, podendo também ser um potencial alvo terapêutico. Mostrámos também a 
importância de entender que mutações no gene ALK estão associadas com predisposição 
hereditária, permitindo orientar o rastreio nas famílias com mutações germinativas no gene 
ALK. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LIST OF ABREVIATIONS 
 
  
 
 xxxv 
 
LIST OF ABBREVIATIONS 
 
aCGH – array-based comparative genomic hybridization 
AHSCT – autologous hematopoietic stem-cell transplantation 
ALCL – anaplastic large-cell lymphoma  
BM – basement membrane 
CCHS – congenital central hypoventilation syndrome  
CNS – central nervous system 
DAPI – 4’, 6-diamidino-2-phenylindole 
ddNTP – Dideoxynucleotide 
DLBCL – diffuse large B cell lymphoma  
DNA – Deoxyribonucleic acid  
dNTP – deoxynucleoside triphosphate  
ECM – extracellular matrix 
EFPE – formalin-fixed paraffin-embedded  
EFS – event-free survival 
ERK – extracellular signal-regulated kinase  
FISH – Fluorescence in situ hybridization  
GM-CSF – granulocyte-macrophage - colony-stimulating stimulating factor 
GN – Ganglioneuroma 
GNB – Ganglioneuroblastoma  
GWAS – genome-wide association studies  
HSCR – Hirschsprung disease 
ICCC – International Classification of Childhood Cancer 
IHC – immunohistochemistry  
IL2 – interleukin 2 
IMT – inflammatory myofibroblastic tumor  
INRG – International Neuroblastoma Risk Group 
 xxxvi 
 
INRGSS – International Neuroblastoma risk group staging system 
INSS – International Neuroblastoma Staging System 
JAK – Janus kinase 
LOH – loss of heterozygosity  
MAPK – mitogen activated protein kinase 
MK – midkin 
MKI – Mitosis Karyorrheris Index  
MLPA – multiplex ligation-dependent probe amplification  
mRNA – messenger ribonucleic acid 
NB – Neuroblastoma 
NSCLC – non-small-cell lung cancer  
PCR – polymerase chain reaction  
PI3K – phosphoinositide 3-kinase 
PTN – pleiotropin  
RAS – rat sarcoma oncogene 
RCC – renal cell carcinoma 
RT – room temperature 
SCC – squamous cell carcinoma  
SNP – single nucleotide polymorphism  
STAT – signal transducer and activator of transcription  
TKD – tyrosine kinase domain 
 
GENES 
ALK – anaplastic lymphoma kinase 
APC – adenomatous polyposis coli 
ARID1A – AT-rich interaction domain 1A 
ARID1B – AT-rich interaction domain 1B 
ATRX – ATP-dependent helicase 
BARD1 – BRCA1-associated ring domain 1 
 xxxvii 
 
CASC15 – cancer susceptibility candidate 15 
CHEK2 – checkpoint kinase 2 
CLPTM1L – cleft lip and palate transmembrane protein 1-like protein 
DDX4 – DEAD (Asp-Glu-Ala-Asp) box polypeptide 4 
DUSP12 – dual specificity phosphatase 12 
EML4 – echinoderm microtubule-associated protein-like 4 
GAB2 – GRB2 Associated Binding Protein 2 
HACE1 – repeat containing E3 ubiquitin protein ligase 1 
HRAS – Harvey rat sarcoma viral oncogene homolog  
IL31RA – Interleukin 31 receptor A 
LMO1 – LIM domain only 1 
MYCN – MYCN proto-oncogene, bHLH transcription factor  
NF1 – neurofibromin 1 
NPM – nucleophosmin 
PHOX2B – paired-like homeobox 2B 
PINK1 – PTEN-induced putative kinase 1 
PTPN11 – protein tyrosine phosphatase, nonreceptor type 11 
SDHB – succinate dehydrogenase complex iron sulfer, subunit B  
TERT – telomerase reverse transcriptase 
TIAM1 – T-cell lymphoma invasion and metastasis 1 
TP53 – tumor protein 53
  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I. INTRODUCTION 
  
 
  
  
 1 
 
I. INTRODUCTION 
 
Cancer arises from the progressive accumulation of genetic and epigenetic 
alterations on cells, that acquire the ability to uncontrollable proliferation, suppression of 
apoptosis, invasion, metastization and stimulation of angiogenesis (Tornesello et al., 2015).  
Cancer is a major health problem and is one of the most common cause of death 
worldwide (Ferlay et al., 2015; Torre et al., 2015). In general, cancer rates are higher in 
more developed countries, however, these have been increasing in developing ones, 
maybe due to the adoption of lifestyle behaviors that increase cancer risk, such as smoking, 
a poor diet, sedentariness and reproductive changes (Torre et al., 2015). Endogenous 
factors may also influence the individual risk for cancer, such as endogenous hormones, 
medical history and/or genetic susceptibility (Siegel et al., 2016).  
Although cancer incidence increases with age, there is a small proportion of cases, 
less than 2% of the global cancer burden, diagnosed in children and young adults (aged 0 
to 19 years) (Pritchard-Jones and Sullivan, 2013). In more developed countries, cancer is 
the second commonest cause of childhood mortality (Kaatsch, 2010; Siegel et al., 2016).  
Childhood cancer is classified according to the International Classification of 
Childhood Cancer (ICCC). On the first year of life, neuroblastomas, retinoblastomas and 
nephroblastomas combined account for about half of all malignancies, while leukemias, 
central nervous system (CNS) tumors and lymphomas predominate in ages ranging from 1 
to 14 years. In adolescents (aged 15 to 19 years), a smaller proportion of cancers diagnosed 
are leukemias and a larger proportion are lymphomas and CNS tumors (Kaatsch, 2010; 
Siegel et al., 2016). Among all ages (0 to 19 years), brain cancer is the commonest leading 
cause of cancer death (Siegel et al., 2016). 
Cancer incidence rates increased in children and adolescents by 0.6% per year from 
1975 to 2012. In contrast, the 5-year relative survival rate improved from 58% to 83%, for 
all cancer sites combined (Siegel et al., 2016). The improvements in treatment and the novel 
approaches to the design of clinical trials may explain the substantial progress for all major 
childhood cancers. 
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1. Neuroblastoma 
The term neuroblastoma (NB) is commonly used to refer to a spectrum of peripheral 
neuroblastic tumors, including neuroblastoma, ganglioneuroblastoma (GNB) and 
ganglioneuroma (GN). NB is a malignancy of early childhood that arises from the aberrant 
growth of neural crest progenitor cells during the development of sympathetic nervous 
system (Maris, 2010).  
 
1.1. Epidemiology 
NB is the most frequent extracranial solid tumor in childhood accounting for more 
than 7% of malignancies in patients younger than 15 years-old. This pediatric cancer varies 
greatly between age groups, with a peak of incidence in children less than four years old, 
with boys being, in general, more affected than girls (Kaatsch, 2010; Park et al., 2013).  
The median age at diagnosis of NB patients is about 18 months (Matthay et al., 
2016), and often presents with widespread metastatic disease, resulting in survival rates 
less than 50% (Maris, 2010; Pugh et al., 2013). It accounts for about 10 to 12% of childhood 
cancer mortality (Park et al., 2013; Pugh et al., 2013).  
The age-standardized incidence rate varies internationally. A relatively higher 
incidence is observed in developed countries than in developing ones. The incidence rate 
of NB in Europe, about 11.2 per million children (Kaatsch, 2010), is very close to that in 
North America, which is about 10.5 per million children (Park et al., 2013). Furthermore, 
differences between Black and White races are observed. Black race from both Africa and 
North America seems to show a significantly lower NB incidence rate than Caucasians 
(Stiller and Parkin, 1992). However, in Black race, NB is diagnosed at an older age, with a 
higher prevalence of high-risk disease and a worse outcome (Henderson et al., 2011; Stiller 
and Parkin, 1992). 
In Portugal, the incidence rate of NB is not established. The crude incidence of 
malignant childhood cancers diagnosed in Portugal from 2000 to 2006 was 9.2 per 100 000 
per year, comparable to 14.8 in Southern Europe, and an improvement of 5-year age-
standardized survival has been recorded from 1999 to 2007 (Gatta et al., 2014). 
Additionally, the data of children diagnosed with NB in Southern Europe showed an 
improvement of survival, from 65% to 71.9% (Gatta et al., 2014).  
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1.2. Diagnostic and risk classification 
Determination of tumor staging and its biology is performed at the time of diagnosis 
and requires a range of exams that include analysis of different plasmatic and urinary 
parameters, radiographic images and histological and genetical assessment. Therapeutic 
decision is based on stratification into different risk groups according to the International 
Neuroblastoma Risk Group (INRG).  
The normal neural crest cells differentiate into sympathetic neurons, chromaffin, 
Schwann and satellite cells, however, NB tumors contain immature sympathetic neurons 
and Schwann cells (Ratner et al., 2016). In 1984, Shimada et al. introduced a new 
terminology and classification of peripheral neuroblastic tumors. Tumors were classified as 
favorable or unfavorable histology according to the amount of Schwannian stroma (stroma-
poor or stroma-rich), degree of neuroblast differentiation, patient’s age at diagnosis and 
Mitosis Karyorrheris Index (MKI) of the tumor.   
NB tumors are assigned to one of four morphologic categories based on the scheme 
proposed by Shimada et al. (1984) and morphologic features described by Joshi and 
colleagues (Joshi et al., 1992; Joshi et al., 1996): neuroblastoma (Schwannian stroma-
poor); ganglioneuroblastoma, intermixed (Schwannian stroma-rich); ganglioneuroma 
(Schwannian stroma-dominant), and ganglioneuroblastoma, nodular (composite 
Schwannian stroma-rich/stroma-dominant and stroma-poor) (Shimada et al., 1999) 
(Supplementary Table 1). 
The International Neuroblastoma Staging System (INSS) was stablished in 1986, 
for a common diagnosis and staging (Supplementary Table 2). (Brodeur et al., 1993). 
However, a new staging scheme, the International Neuroblastoma Risk Group staging 
system (INRGSS), was proposed in 2009 by Monclair et. al, based on clinical criteria and 
tumor imaging rather than extent of surgical resection, allowing a pretreatment staging and 
risk assessment (Table I.1).  
 
 
Table I.1: International Neuroblastoma Risk Group Staging System (Monclair et al., 2009). 
 
INTRODUCTION 
 
4 
 
After disease staging, each patient is stratified, based on clinical and molecular risk 
factors (such as MYCN amplification, 11q aberration and ploidy) as very low-risk, low-risk, 
intermediate-risk or high-risk, with 5-year event-free survival (EFS) of more than 85%, 75% 
to ≤ 85%, ≥ 50% to ≤ 75%, or less than 50%, respectively (Cohn et al., 2009). The 
stratification in pretreatment risk groups, summarized in Table I.2, helps the clinicians to 
decide the best course of treatment (Pinto et al., 2015). 
 
Table I.2: International Neuroblastoma Risk Group pretreatment classification schema 
(Pinto et al., 2015). 
 
1.3. Clinical presentation 
Primary tumors can arise anywhere in the sympathetic nervous system. The majority 
of tumors have an abdominal location, with at least half of these arising in the adrenal 
medulla. The neck, chest and pelvis are other sites of disease occurrence (Maris et al., 
2007). The location of primary tumor is associated with different disease clinical and 
biological features. Abdominal and extra-abdominal sites are associated with lower and 
higher survival, respectively, and tumors located in thorax are more predominant in younger 
age patients (Vo et al., 2014).  
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Metastatic disease is detected in approximately half of patients at diagnosis, being 
the most common locations of metastasis the regional lymph nodes, cortical bone and bone 
marrow (Maris et al., 2007; Matthay et al., 2016). On the other hand, metastatic involvement 
of lung and brain is rare (DuBois et al., 1999). However, there is a group of patients with 
metastization to the liver, skin and bone marrow in children with less than 18 months of age, 
which represents a clinical stage designed MS (D'Angio et al., 1971; Evans et al., 1971). 
This specific stage is diagnosed in about 5% of the cases and almost always regress 
spontaneously (DuBois et al., 1999; Maris et al., 2007; Matthay et al., 2016).  
The presentation of symptoms depends on the site of the primary tumor, the 
extension of metastatic disease and the presence or absence of paraneoplastic syndromes 
(Maris et al., 2007; Matthay et al., 2016).  
 
1.4. Treatment 
NB treatment includes surgery, chemotherapy, radiotherapy, high-dose 
chemotherapy/radiotherapy with autologous stem cell transplant. It can also be used 
retinoid acid therapy, immunotherapy, and more recently targeted therapy (Pinto et al., 
2015; Simon et al., 2017).  
Low- or intermediate-risk patients have excellent outcomes. For low-risk patients 
without symptoms, surgery alone can be curative. Symptomatic low-risk patients at 
diagnosis can receive a less-intensive chemotherapy without radiotherapy. However, some 
observational studies demonstrated a subset of infants with localized tumors that can be 
cured without any treatment, including surgery (Pinto et al., 2015; Simon et al., 2017). 
Regarding the intermediate-risk patients, a more intensive regimen of chemotherapy and 
radiotherapy is needed for older patients with unfavorable histology tumors (Pinto et al., 
2015).  
Treatment regimens of high-risk patients include induction chemotherapy and 
surgery, consolidation chemotherapy with myeloablative chemotherapy with autologous 
hematopoietic stem-cell transplantation (AHSCT) and irradiation, and post consolidation 
therapy to treat minimal residual disease (Pinto et al., 2015) (Figure I.2).  
Resection of the primary tumor is performed during or after induction therapy and 
the disadvantage of incomplete resection might be compensated by intensified local 
radiotherapy (Simon et al., 2017). Induction therapy consists in a combination of agents, 
including cisplatin, cyclophosphamide, carboplatin, doxorubicin, etoposide, topotecan and 
vincristine (Pinto et al., 2015; Simon et al., 2017). Consolidation therapy consists in 
myeloablative chemotherapy regimens with autologous stem cell transplantation. External 
beam radiotherapy is recommended followed by myeloablative chemotherapy and AHSCT 
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for cases with residual tumor tissue present after surgery and induction therapy (Simon et 
al., 2017).   
Despite the improvement in EFS with myeloablative chemotherapy followed by 
AHSCT, all patients who achieve a clinical remission relapse months to years after 
transplantation. A post-consolidation therapy with the combination of the ch14.18/SP2/0 
anti-GD2 antibody (Dinutuximab), CSF2 (formerly granulocyte-macrophage colony-
stimulating factor or GM-CSF), interleukin 2 (IL2) and isotretinoin is considered a standard 
first-line treatment for these patients (Matthay et al., 2016; Pinto et al., 2015; Simon et al., 
2017). 
 
2. Genetic alterations in NB 
2.1. Germline mutations 
An hallmark of NB is its heterogeneity in clinical presentation, course and overall 
prognosis (Bosse and Maris, 2016). It presents several types of unique biologic behaviors, 
such as spontaneous regression, maturation and high proliferation (Shimada et al., 1999), 
but, its etiology is largely unknown. 
About 1 to 2% of NB are inherited, in an autosomal dominant manner (Azarova et 
al., 2011; Mosse et al., 2008). Germline mutations in the anaplastic lymphoma kinase (ALK) 
and paired-like homeobox 2B (PHOX2B) genes are responsible for the majority of 
hereditary cases (Azarova et al., 2011; Parodi et al., 2014). Activating mutations in the ALK 
gene, located on chromosome 2p23, are the germline alterations more frequently 
Figure I.1: Current standard-of-care treatment strategy for high-risk neuroblastoma (NB) (Pinto et al., 
2015). 
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associated with hereditary NB, being identified in about 50% of the cases (Mosse et al., 
2008; Schleiermacher et al., 2014).  
There is an association of NB with other genetically determined neurocristopathies, 
such as Hirschsprung disease (HSCR) and/or congenital central hypoventilation syndrome 
(CCHS). Alterations in PHOX2B gene, located on chromosome 4p, are the major disease-
causing of CCHS, but, germline mutations have also been identified in NB patients with 
HSCR and/or CCHS (Mosse et al., 2004; Trochet et al., 2004). However, PHOX2B 
mutations explain only a small proportion of hereditary NB (less than 10%) (Mosse et al., 
2008; Raabe et al., 2008). Although more rarely, few NB cases are associated with genetic 
syndromes with underlying rat sarcoma oncogene-mitogen activated protein kinase (RAS-
MAPK) pathway germline mutations, such as Neurofibromatosis type 1, Noonan syndrome 
and Costello syndrome (Figure I.1 [left]) (Bosse and Maris, 2016; Schleiermacher et al., 
2014).  
Mutations in other genes that can predispose to NB have been identified, but the 
clinical relevance of these alterations remains poorly understood. In 2013, Pugh et al. found 
the tumor protein 53 (TP53) p.Pro219Ser mutation in NB patients, consistent with prior 
reports of NB being weakly associated with Li-Fraumeni syndrome (Birch et al., 2001). Two 
other germline variants in the TP53 gene were found as being strongly associated with NB 
(Diskin et al., 2014). Other studies have identified putative damaging mutations in 
checkpoint kinase 2 (CHEK2), PTEN-induced putative kinase 1 (PINK1), BRCA1-
associated ring domain 1 (BARD1), adenomatous polyposis coli (APC) and succinate 
dehydrogenase complex iron sulfur, subunit B (SDHB) genes in small percentages of NB 
patients (Figure I.1 [middle]) (Pugh et al., 2013; Zhang et al., 2015).  
Genome-wide association studies (GWAS) identified common DNA variations that 
can influence the malignant transformation in NB. Common single nucleotide 
polymorphisms (SNPs) were identified in cancer susceptibility candidate 15 (CASC15), 
BARD1, LIM domain only 1 (LMO1), HECT domain and ankyrin repeat containing E3 
ubiquitin protein ligase 1 (HACE1), which were associated with high-risk of NB development 
(Capasso et al., 2009; Diskin et al., 2012; Russell et al., 2015; Wang et al., 2011). On the 
other hand, the SNPs identified in dual specificity phosphatase 12 (DUSP12), DEAD (Asp-
Glu-Ala-Asp) box polypeptide 4 (DDX4) and interleukin 31 receptor A (IL31RA) were 
associated with the low-risk NB (Figure I.1 [right]) (Bosse and Maris, 2016; Nguyen le et al., 
2011). 
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2.2. Chromosomal changes 
Oncogenes appear to be activated from their normal state due to mutations, gene 
amplification or gene fusion (Ponder, 1992). In 1984, the amplification of MYCN gene, 
located on chromosome 2p24.1, was described for the first time in NB patients (Brodeur et 
al., 1984). MYCN amplification, present in approximately 20 to 25% of all primary tumors 
(Maris et al., 2007), is associated with advanced stages of disease and with poor prognosis 
(Brodeur et al., 1984; Seeger et al., 1985). Around 6% of tumors show only one or a few 
additional MYCN copies, defined as MYCN-gain, which is also associated with a worse 
prognosis in diploid tumors (Spitz et al., 2004). Additionally, deletion of chromosome 11q, 
which is present in 35 to 45% of the cases, is inversely associated with MYCN amplification 
(Maris et al., 2007), however, it is correlated with MYCN copy number gain (Spitz et al., 
Figure I.2: Rare and common genomic variants that predispose to NB.  [left] mutations in anaplastic 
lymphoma kinase (ALK) and paired-like, homeobox 2B (PHOX2B) are inherited in an autosomal dominant 
Mendelian manner, with incomplete penetrance. Additionally, NB can also arise in a subset of genetic 
syndromes with germline mutations in tumor protein 53 (TP53), succinate dehydrogenase complex iron sulfur, 
subunit B (SDHB), Harvey rat sarcoma viral oncogene homolog (HRAS), protein tyrosine phosphatase, non-
receptor type 11 (PTPN11) and neurofibromin 1 (NF1). [middle] Low-frequency damaging mutations with an 
intermediate effect size. [right] More common alleles with a modest effect size, specifically to high-risk (white) 
or low-risk (orange) NB [Adapted from (Bosse and Maris, 2016)]. 
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2004). Therefore, the presence of deletion of 11q has emerged as a powerful prognosis 
biomarker of a worse prognosis in patients without MYCN amplification (Attiyeh et al., 2005).  
Additionally, other chromosome changes have been identified with prognostic value 
in NB patients, including deletions of chromosomes 1p, 3p, and 4p, and a gain of 1 to 3 
copies of chromosome 17q region (Janoueix-Lerosey et al., 2009). In general, tumors with 
gains of whole-chromosome, resulting in hyperdiploidy, are associated with favorable 
features such as non-metastatic disease or stage MS and younger age at diagnosis, 
whereas tumors with segmental chromosome alterations are associated with more 
aggressive forms of disease. The tumor overall genomic alteration pattern defines specific 
genetic groups with different clinical outcomes (Bosse and Maris, 2016; Janoueix-Lerosey 
et al., 2009; Oberthuer et al., 2009).  
These segmental genetic aberrations can be assessed by interphase fluorescence 
in situ hybridization (FISH), array-based comparative genomic hybridization (aCGH), 
polymerase chain reaction (PCR) or multiplex ligation-dependent probe amplification 
(MLPA) techniques (Ambros et al., 2009). The assessment of tumor cell DNA content 
(ploidy) was shown to influence the prognosis in children younger than 2 years at diagnosis 
(Look et al., 1991; Maris et al., 2007) and is assessed by flow or static cytometry, being 
classified as diploid or hyperdiploid (near-triploid or penta/hexaploidy) (Ambros et al., 2009). 
Allelic loss of chromosome 1p, identified in 25 to 35% of all NB, seems to be 
independent of patient’s age and stage of disease, and is one of the most powerful 
prognostic indicators of a worse outcome (Maris et al., 2007). A strong correlation exists 
between MYCN amplification and chromosome 1p loss of heterozygosity (LOH), is 
demonstrated, both correlated with poor clinical outcome and occurring together mainly in 
more advanced stages and in patients older than one-year (Caron et al., 1996; Fong et al., 
1989; Spitz et al., 2002). Aberrations of chromosome 17q are the most common 
chromosomal alterations described in NB patients, occurring in at least 50% of the tumors 
(Bosse and Maris, 2016; Maris et al., 2007). The chromosome 17q gain is characteristic of 
advanced tumors and are found in patients older than one-year, being strongly associated 
with deletion of 1p and MYCN amplification. The principal mechanism involved in partial 
gain of 17q is an imbalanced translocation with 1p (Bown et al., 1999; Caron et al., 1996).  
 
2.3. Somatic point mutations 
Although chromosomal aberrations are common in NB, with a well-stablished 
influence in patient’s outcome, point mutations are quite rare. Some studies of whole-
genome sequencing have described mutations in cancer-related genes in NB tumors, which 
occur more frequently in high-risk patients. Altogether, these studies showed the 
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occurrence of ALK activating mutations in 7 to 14% of sporadic cases, ALK amplification in 
approximately 2% and more rarely other cytogenetic rearrangements of this gene (Molenaar 
et al., 2012; Mosse et al., 2008; Pugh et al., 2013). Mutations and deletions in ATP-
dependent helicase (ATRX) gene have been associated with children older than 5 years 
old with metastatic disease and have been described as mutually exclusive with MYCN 
amplification. ATRX plays a significant role in regulating adenosine triphosphate – 
dependent chromatin remodeling, nucleosome assembly, and telomere maintenance. 
These mutations were associated with a lower ATRX mRNA expression and long telomeres 
(Cheung et al., 2012; Molenaar et al., 2012; Pugh et al., 2013).  
Rearrangements in the telomerase reverse transcriptase (TERT) gene were also 
found in 23% of high-risk NB. Increased TERT gene copy number appears to promote 
metastasis, in absence of MYCN amplification (Cobrinik et al., 2013; Valentijn et al., 2015). 
Chromothripsis, a located shredding of a chromosomal region with subsequent random 
reassembly of the fragments, has been found in 18% of high-risk patients, and was also 
associated with a poor prognosis (Molenaar et al., 2012).  Additionally, an intragenic 
hemizygous deletion targeting the AT-rich interaction domain 1B (ARID1B) gene and an 
insertion mutation in the homologous AT-rich interaction domain 1A (ARID1A) gene, both 
chromatin remodeling genes, were found in 11% of NB cases and were associated with 
early treatment failure and lower survival (Sausen et al., 2013). Although more rarely, 
mutations in T-cell lymphoma invasion and metastasis 1 (TIAM1) gene (3%), a central 
regulator of cellular polarity and neuritogenesis (Molenaar et al., 2012), and in PTPN11 
gene (2.9%) have also been described (Pugh et al., 2013).  
 
3. The anaplastic lymphoma kinase (ALK) gene 
The ALK gene, located on chromosome 2p23, codes for a membrane associated 
tyrosine kinase receptor, which is a member of the insulin receptor protein-tyrosine kinase 
superfamily. The ALK gene encodes a mature protein of 220 kDa that migrates as two 
protein isoforms: the 220 kDa full-length receptor and the truncated 140kDa protein that 
results from extracellular cleavage. This protein has an extracellular domain, a 
transmembrane segment and an intracellular domain, which contains a protein kinase 
domain (Azarova et al., 2011; Roskoski Jr, 2013). It is thought that, in mammalians, ALK 
plays a key role in the development and function of nervous system during the neural 
development. This gene is preferentially expressed in brain and spinal cord, being highly 
expressed in neonatal brain (Iwahara et al., 1997; Roskoski Jr, 2013).   
The normal ALK activation by the growth factors ligands pleiotropin (PTN) and 
midkine (MK) results in the activation of many different pathways that are strictly 
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interconnected and overlapping. These include the rat sarcoma oncogene-extracellular 
signal-regulated kinase (RAS-ERK) pathway, the janus kinase 3-signal transducer and 
activator of transcription 3 (JAK3-STAT3) pathway and the phosphoinositide 3-kinase-Akt 
(PI3K-Akt) pathway, which participate in cell proliferation, cell survival, inhibition of 
apoptosis and also in induction of neuronal cell differentiation through the MAPK pathway 
(Azarova et al., 2011). A variety of ALK gene alterations have been described in several 
types of tumors, including mutations, amplifications, deletions and translocations leading to 
an aberrant activity of ALK (Chiarle et al., 2008).  
 
3.1. ALK changes in various cancers 
ALK seems to be a “hotspot” for translocation to a wide variety of loci. A translocation 
involving chromosomes 2p and 5q, t(2;5)(p23;q35), which generates a fusion protein (NPM-
ALK), was described for the first time in the anaplastic large-cell lymphoma (ALCL), the first 
disorder associated with ALK fusion proteins (Morris et al., 1994; Roskoski Jr, 2013). Since 
then, 22 other genes have been described as rearranged with ALK in several types of 
cancer, including inflammatory myofibroblastic tumor (IMT), non-small-cell lung cancer 
(NSCLC), diffuse large B cell lymphoma (DLBCL), squamous cell carcinoma (SCC) and 
renal cell carcinoma (RCC) (Hallberg and Palmer, 2013). Furthermore, NSCLC patients 
harboring rearrangements involving ALK (ALK-EML4, most frequently) are eligible for 
targeted therapy with ALK inhibitors (Solomon et al., 2014).  
More recently, increased ALK activity due to overexpression of ALK or point 
mutations has been reported as playing a primary role in the pathogenesis, aggressiveness 
and lethality of NB (Roskoski Jr, 2013). 
 
3.2. ALK rearrangements in NB  
Since 2002, several works were published reporting the high incidence of ALK 
mutations and gene amplifications in advanced sporadic NB tumors (Bagci et al., 2012; 
Carén et al., 2008; Chen et al., 2008; George et al., 2008; Janoueix-Lerosey et al., 2008; 
Miyake et al., 2002; Mosse et al., 2008; Osajima-Hakomori et al., 2005; Subramaniam et 
al., 2009).  
Miyake et al. (2002) and Osajima-Hakomori et al. (2005) showed that the 
constitutively activation of ALK gene by amplification plays a role in the pathophysiology of 
NB, resulting in hyperphosphorylation of ShcC, MAPK and Akt proteins. They showed that 
ALK inhibition suppresses tyrosine phosphorylation of ShcC and blocks MAPK and Akt, 
resulting in apoptosis. Furthermore, ALK amplification has been identified in several studies 
in approximately 2% of cases and is associated with a worse outcome (Azarova et al., 
INTRODUCTION 
 
12 
 
2011). Additionally, ALK has been shown to be co-amplified with MYCN gene, which is 
located on 2p24.3 very close to the ALK locus, in around 7 to 15% of all MYCN amplified 
tumors (Azarova et al., 2011; Bagci et al., 2012; De Brouwer et al., 2010; Wang et al., 2013). 
However, Chen et al. (2008) suggested that ALK and MYCN loci can also be amplified in 
separate amplicons.  
Additionally, there is a high frequency of tumors harboring a partial gain of 
chromosome 2p region, encompassing the ALK gene (17 to 45%) (Bagci et al., 2012; Carén 
et al., 2008; Chen et al., 2008; Mosse et al., 2008). Moreover, ALK gene copy number is 
strongly correlated with mRNA and protein expression levels, which is significantly 
correlated with a worse overall survival (De Brouwer et al., 2010; Passoni et al., 2009). 
More recently, a new mechanism of aberrant ALK activation by balanced or 
unbalanced translocations and deletions has been suggested (Table I.3). A balanced 
translocation between the ALK gene in chromosome 2 and the CLPTM1L gene in 
chromosome 5 was described in a cell line, resulting in an out-of frame fusion transcript, but 
its biologic function remains to be defined (Cazes et al., 2013). Unbalanced translocations 
between chromosome 2 and chromosomes 4 and 11, resulting in 2p gain, were described 
in tumors samples, nevertheless, since gene fusion occurs in opposing transcriptional 
directions, a chimeric transcript it is unlikely to be produced (Fransson et al., 2015). 
Additionally, three different deletions, combined with ALK locus amplification, were 
described as leading to truncated ALK variants, which exhibit oncogene properties and are 
associated with tumor aggressiveness (Cazes et al., 2013; Fransson et al., 2015; Okubo et 
al., 2012). This pattern of rearrangements and the multiple breakpoints observed in NB 
tumor samples may correspond to the phenomenon of chromothripsis, recently reported in 
aggressive NB (Cazes et al., 2013; Fransson et al., 2015; Molenaar et al., 2012; Wang et 
al., 2013).  
 
Table I.3: ALK gene rearrangements described in NB. 
 
 
 
INTRODUCTION 
 
13 
 
3.3. Somatic ALK point mutations in NB 
Somatic mutations have been identified in approximately 7 to 14% of NB patients, 
mainly occurring in the catalytic loop or the C-helix kinase domains (Table I.4) (Mosse et 
al., 2008). Two mutational hotspots, at positions R1275 on exon 25 and F1174 on exon 23, 
have been described. These mutations occur in the kinase domain and result in the 
constitutive active forms of the protein, leading to constitutive phosphorylation of ALK and, 
consequently, phosphorylation of downstream targets, such as STAT3, Akt and ERK (Chen 
et al., 2008; De Brouwer et al., 2010; George et al., 2008). These mutations were found 
across the entire spectrum of disease, presenting similar frequencies in cases with or 
without MYCN amplification (De Brouwer et al., 2010; Mosse et al., 2008). Furthermore, no 
differences in survival of patients with ALK mutations were observed, suggesting that ALK 
mutations themselves are not an adverse prognostic factor (Chen et al., 2008; De Brouwer 
et al., 2010). However, when the survival was compared between different mutations, 
patients with a F1174 mutation have shown a worse survival than those with a R1275 
mutation or wild-type, which can be explained by the high frequency of MYCN amplification 
in F1174 mutation carriers (De Brouwer et al., 2010). Moreover, ALK copy number gain was 
not frequently found in tumors harboring ALK mutations, suggesting that 2p gain is not a 
common mechanism of increasing mutated ALK expression (De Brouwer et al., 2010; 
Passoni et al., 2009).  
The clinical role of ALK mutations or amplification remains controversial (Bagci et 
al., 2012; Brodeur et al., 1984; Carén et al., 2008; Chen et al., 2008; De Brouwer et al., 
2010). However, it seems to be clear that more aggressive and metastatic tumors exhibit a 
higher expression of ALK comparatively to localized NB, even without ALK gene alterations, 
suggesting that increased ALK expression might be functionally relevant in NB. It is possible 
that patients with wild-type ALK overexpression might benefit from ALK inhibitors therapy, 
in addition to those harboring ALK amplification or point mutations (Hallberg and Palmer, 
2013; Passoni et al., 2009). 
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Table I.4: ALK somatic mutations described in NB patients. 
 
 
3.4. Germline ALK mutations in hereditary NB 
Hereditary NB is an autosomal dominant disease, with incomplete penetrance. This 
was the first example of a pediatric cancer associated with germline mutations in an 
oncogene (Mosse et al., 2008).  ALK germline mutations are identified in approximately 
50% of NB families (Table I.5) (Mosse et al., 2008). The mutations R1275Q (Janoueix-
Lerosey et al., 2008; Mosse et al., 2008), R1192P (Bourdeaut et al., 2012; Janoueix-
Lerosey et al., 2008; Mosse et al., 2008) G1128A (Mosse et al., 2008) and T1151R 
(Bourdeaut et al., 2012) have been described in families with NB. 
The disease diagnosis at early age, presence of multifocal disease and familial 
recurrence of neuroblastic tumors are characteristics highly suggestive of a hereditary NB 
(Bourdeaut et al., 2012; Mosse et al., 2008). Mosse et. al. only found ALK mutations in NB 
families characterized by at least two affected individuals, related in first-degree. Bourdeaut 
et al. (2012) identified ALK germline mutations in 3 of 16 (18.75%) multifocal cases, 
suggesting that this clinical feature might be strongly indicative of an ALK-related 
predisposition in absence of familial history. However, younger age is not a major relevant 
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criterion indicative of ALK-related predisposition, as diagnoses have been reported at the 
age of three, 12 and 15 years in individuals with germline R1275Q and R1192P mutations 
(Janoueix-Lerosey et al., 2008). 
The R1275Q ALK gene mutation is the most frequent mutation in hereditary NB, and 
is also one of the mutational hotspots in sporadic NB (Azarova et al., 2011; Mosse et al., 
2008). This mutation was described as arising de novo in two families inherited either from 
an affected or unaffected parent (Mosse et al., 2008). On the other hand, the mutation 
R1192P previously described in four families was always inherited from an unaffected 
parent (Bourdeaut et al., 2012; Hallberg and Palmer, 2013; Janoueix-Lerosey et al., 2008; 
Mosse et al., 2008). A de novo germline ALK mutation at position F1174, was found in a 
case of congenital NB with severe encephalopathy (de Pontual et al., 2011), indicating that 
it might cause embryonic lethality in most of the cases (Azarova et al., 2011; Bourdeaut et 
al., 2012; De Brouwer et al., 2010).  
 
Table I.5: ALK germline mutations described in hereditary NB. 
 
 
3.5. ALK inhibitors in neuroblastoma treatment 
The first ALK inhibitor tested in a clinical trial was Crizotinib, an oral bioavailable 
small molecule inhibitor approved for EML4-ALK positive NSCLC patients. It is an ATP-
competitive molecule that prevents subsequent autophosphorylation necessary for further 
signal transduction. This drug was studied for the treatment of NB patients with either 
amplification or mutation in the ALK gene (Azarova et al., 2011). Some in vitro and in vivo 
studies have shown that Crizotinib is more potent in NB cell lines and xenografts with ALK 
amplification or the R1275Q mutation than in those with F1174L mutation, suggesting that 
the latter may promote resistance to the drug (Bresler et al., 2011). In a pediatric phase 1 
and phase 2 trial of Crizotinib, two NB patients with ALK germline mutations responded to 
this therapy, but further studies are required (Mosse et al., 2013). However, more recent 
results suggest that the combination of Crizotinib with conventional chemotherapy may 
provide superior anti-tumor activity than each approach separately (Krytska et al., 2016).   
INTRODUCTION 
 
16 
 
Another ALK inhibitor is Entrectinib, a potent inhibitor of cell proliferation that induces 
cell death, causing cell cycle arrest. It was able of decrease growth and proliferation of ALK-
amplified cell lines, however, shows low efficiency in ALK mutated cells (Aveic et al., 2016). 
Other ALK inhibitors have been studied, such as the potent second-generation ALK inhibitor 
Alectinib, which is active against some ALK mutations including, F1174L and R1275Q, 
indicating that this drug is able to overcome Crizotinib-induced chemoresistance (Lu et al., 
2017). 
More recently, Infarinato et al. (2016) described a novel ALK inhibitor with a superior 
potency than the others described so far. The ALK/ROS1 inhibitor PF-06463922 seems to 
exert activity in ALK-driven NB models with primary Crizotinib resistance. This new drug 
appears to be a key to overcome the ALK-driven therapy resistance, which is the biggest 
challenge in NB treatment with ALK inhibitors.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
II.  AIMS OF THE STUDY 
 
 
  
 
 
 19 
 
II. AIMS OF THE STUDY 
 
Due to the recently clinical implications of ALK changes in NB patients, the general 
aim of this work was to test for these alterations in NB patients diagnosed at the Portuguese 
Institute of Oncology of Porto (IPO-Porto) from 2003 to 2016. The specific aims were:  
➢ To search for ALK fusion genes in neuroblastomas;   
➢ To compare the pattern of amplification of the ALK and MYCN genes in 
neuroblastomas;  
➢ To identify somatic and germline ALK tyrosine kinase domain (TKD) point 
mutations;  
➢ To relate the ALK alterations with clinical outcome in neuroblastoma patients.  
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
III. MATERIAL AND METHODS 
 
 
  
 
 23 
 
III. MATERIAL AND METHODS  
 
1. Patients and sample collection 
A consecutive series of primary NB tumors from 46 patients treated at IPO-Porto 
from 2003 to 2016 and tested for MYCN amplification at the Department of Genetics was 
retrospectively analyzed. The clinical, genetical and pathological data of NB patients were 
recorded and are summarized in Table III.1.  
Forty-one cell suspension samples of primary NB tumors were analyzed for ALK 
gene rearrangements by fluorescence in situ hybridization (FISH). Twenty-nine frozen fresh 
tumor samples were subsequently analyzed by Sanger sequencing for exons 20 to 28 of 
the ALK gene. Twenty-four patients were analyzed by both FISH and Sanger sequencing. 
Whenever possible, normal tissue was analyzed from patients presenting mutation in tumor 
samples. 
 
Table III.1: Clinical and standard genetic information on the NB patients. 
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2. Fluorescence in situ hybridization  
Fluorescence in situ hybridization (FISH) was performed with a dual color, break 
apart probe flanking the ALK gene, ALK (2p23) Break FISH probe, [Kreatech, Leica Biosystems, Nussloch, 
Germany] (Figure III.1). Slides were prepared fresh from cultured cells fixed with 
methanol:acetic acid. Co-denaturation was performed at 80°C for 8 min, followed by 
hybridization at 37°C in humidified chamber (ThermoBrite denaturation/hybridization 
system [Leica Biosystems, Nussloch, Germany]) for 18 hours. Post-hybridization washes were done using 
2xSSC/0.1% IGEPAL [Sigma Aldrich] solution at room temperature (RT) for 30 minutes, followed 
by 0.4 x SSC/ 0.3% IGEPAL at 74 °C for 2 min and 2 x SSC/ 0.1% IGEPAL for 5 minutes, 
at RT. Slides were dehydrated by passages through an increasing series of alcohols, 70%, 
85% and 100%, 2 minutes each and air dried. DAPI (4’, 6-diamidino-2-phenylindole) [Vector 
Laboratories, Burlingame, California, USA] was applied as a counterstain and results were evaluated with 
a GSL-120 Automated Cytogenetics Platform with a CytoVision Software Version number 
7.4 [Leica Biosystems]. For each sample, at least 50 intact non-overlapping nuclei were scored.  
Fluorescence images corresponding to DAPI, Spectrum Green and Spectrum 
Orange were automatically captured and relative copy number alteration in 2p23 region was 
assessed as previously described (Subramaniam et al., 2009). 
Since centromeric chromosome 2 copy number was available from previous MYCN 
analysis, the status of ALK was calculated for each sample, according to MYCN status 
criteria (Ambros et al., 2009). An abnormal signal pattern was considered representative 
when present in a minimum of 10% of tumor cells. 
Cases were categorized as: 
➢  ALK gain (G), when the number of ALK gene signals was one- to four-times 
greater than the CEP2 signals; 
➢ ALK-ampliﬁed (A), when the number of ALK gene signals was four-times 
greater than the CEP2 signals; 
➢ ALK loss/imbalance (L), when the number of ALK gene signals was less than 
that of CEP2 signals; 
➢ Chromosome 2 polysomy (P), when both CEP2 and ALK signals were 
increased. 
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3. DNA extraction and quantification 
3.1. Extraction of genomic DNA from frozen fresh samples 
A piece of frozen tumor was minced with a scalpel and transferred to a 50ml falcon. 
Four ml of SE buffer (75mM NaCl; 25 mM EDTA), 400µl of SDS (Sodium Dodecyl Sulfate) 
10% and 50µl of proteinase K [Gibco Invitrogen, Carlsbad, CA, USA] (10ng/µl) were added, followed by 
incubation at 55ºC overnight. One ml of NaCl (6M) was added to the lysed sample and 
incubated at 55ºC for 10 minutes. An equal volume of chloroform was added, gently mixed 
for 30 minutes and centrifuged at 4000 rpm for 10 minutes. The aqueous DNA solution was 
transferred to a 15ml falcon and an equal volume of isopropanol 100% was added. The 
precipitated DNA was transferred to an eppendorf with 70% ethanol. Subsequently, ethanol 
was discarded and air dried. Finally, the DNA was eluted in ddH2O and was quantified by 
spectrophotometry with NanoDrop ND-1000® [NanoDrop Technologies, Wilmington, DE, USA].  
 
3.2. Extraction of genomic DNA from paraffin-embedded samples 
Tumor areas containing normal cells were delimited by a pathologist in the 
hematoxylin and eosin (H&E) stained slides of each sample. The corresponding unstained 
slides were immersed in xylene [Sigma-Aldrich, Steinheim, Germany] and then in ethanol 100% [Merck, 
Darmstadt, Germany] for 5 minutes each to remove the paraffin. Tumor areas, which were 
previously delimited by comparison with the correspondent H&E stained slides, were macro 
dissected and transferred to a centrifuge tube and the extraction was performed with a 
 
Figure III.1: ALK (2p23) break FISH probe to detect rearrangements involving the ALK gene. Red critical region 
represents the distal ALK gene region direct-labeled with PlatinumBrighTM550 (3′ALK SpectrumOrange) and 
green critical region represents the proximal ALK gene region direct-labeled with PlatinumBrighTM495 (5′ALK 
SpectrumGreen). 
 
 
 
 
MATERIAL AND METHODS 
 
27 
 
cobas® DNA Sample Preparation Kit, used for manual specimen preparation of formalin-
fixed paraffin-embedded tumor (FFPE) tissues [Roche Diagnostics, Mannheim, Germany], according to 
standard procedures. Finally, the DNA was quantified by spectrophotometry with NanoDrop 
ND-1000® [NanoDrop Technologies, Wilmington, DE, USA].  
 
4. DNA sequencing 
Mutation screening in the tyrosine kinase domain of ALK (exons 20 to 28) was 
performed by Sanger sequencing. For this purpose, DNA was amplified in a solution 
containing 1x PCR gold buffer [Thermo Fisher Scientific, Foster city, CA, USA] (150 mM Tris-HCl, 500 mM 
KCI), 1.5 mM of MgCl2 [Thermo Fisher Scientific], 0.5 mM dNTP mix [Thermo Fisher Scientific], 0.17 mM of 
each primer (reverse and forward) [frilabo, Portugal], 1 U of Taq DNA polymerase [Thermo Fisher 
Scientific], in a final reaction volume of 20 µL. The primer sequences were used from Chen et 
al. (2008) and are summarized in Table III.2. PCR reaction was performed in a thermocycler 
[Gene Amp PCR Systern 9700, Perkin-EImer, Waltham, Massachusetts, USA] according to the following conditions: an 
initial denaturation step at 95°C for 10 min, followed by 35 cycles of 95°C for 45 seconds, 
annealing step at 58°C for 45 seconds and a 45 seconds extension step at 72°C. A final 
extension step was done at 72°C for 10 min. Amplified PCR products were then analyzed 
by electrophoresis in a 2% (w/v) agarose gel [Gibco Invitrogen] stained with green safe [Sigma-Aldrich] 
0.05 µL/mL. 
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Table III.2: Set of primers used to amplifying exons 20 to 28 (Chen et al., 2008).
 
 
Subsequently, the PCR products were purified using the ExoSAP-IT method for the 
removal of primers and dNTPs in excess. Samples were purified adding 2 µL of ExoSAP 
solution, which consists in Exonuclease I [Thermo Fisher Scientific] (20 U/μL) and Fast 
Thermosensitive Alkaline Phosphatase [Thermo Fisher Scientific] (1 U/μL), in a proportion of 1:2, to 
5 µL of the PCR product, followed by incubation at 37ºC for 50 minutes, and enzyme 
inactivation at 80ºC for 15 minutes.   
The purification was followed by the sequencing reaction, in which the BigDye® 
Terminator v1.1 or v3.1 Cycle Sequencing Kit [Applied Biosystems, Foster City, CA, USA] was used. The 
reaction consisted on mixing 3.4 μL of sequencing buffer, 0.5 µL of Big Dye® Terminator 
v1.1 or v3.1, containing dNTPs, ddNTPs-fluorocromes, MgCl2 and Tris-HCl buffer, 0.32 µL 
of one of the primers (forward or reverse), and bidestilled sterile water [B. Braun, Foster City, CA, USA] 
and 1 µL of the previously purified DNA to reach a final reaction volume of 10 µL. The 
sequencing reaction was performed and consisted of an initial denaturation step at 95ºC for 
4 minutes, followed by 35 cycles of denaturation at 96ºC for 10 seconds, annealing at 50ºC 
for 10 seconds and extension at 60ºC for 2 minutes, with a final extension of 60ºC for 10 
minutes. In order to remove excess of dNTPs, labeled ddNTPs, and non-incorporated 
primers, the sequencing products were purified with IIlustra Sephadex® G-50 fine [GE 
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Healthcare, Life Sciences, Cleveland, USA], according to standard procedures. After purification, 15 μL of 
Hi-DiTM Formamide [Applied Biosystems] were added to the sequencing products to help stabilize 
the single stranded DNA. The products were then analyzed in a 3500 Genetic Analyzer 
[Applied Biosystems] by capillary electrophoresis. The electropherograms of each sample were 
analyzed with the Sequencing Analysis Software v5.4 [Applied Biosystems]. All of them were 
examined at least twice, reviewed manually and with the Mutation Surveyor® DNA Variant 
Analysis Software v4.0.8 [Softgenetics, State College, PA, USA]. 
A second PCR amplification was performed in all positive samples, followed by DNA 
Sanger sequencing of both strands. All ALK variants were described according to the 
LRG_488 (NM_004304.3) and to the Human Genome Variations Society guidelines.  
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IV. RESULTS  
 
1. Assessment of ALK rearrangements in NB patients 
ALK rearrangements were screened with a dual-color break-apart probe FISH in 41 
tumor samples from patients with NB. The results are summarized in Table IV.1 and 
illustrated in Figure IV.1.  
 
Table IV.1: ALK alterations assessed by FISH in NB patients. 
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No translocations or inversions were found in our cohort, however, aberrant copy 
number of the ALK gene was observed in 19 cases (46.3%), including ALK amplification in 
one of 41 (2.4%), ALK gain in 13 of 41 (31.7%) and ALK loss/imbalance in five of 41 (12.2%). 
Chromosome 2 polysomy was observed in 15 cases (36.6%) and normal signal pattern was 
observed in the remaining seven cases (17.1%).  
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Figure IV.1: Representative FISH images from four selected NB tumors using a dual color, break apart 
probe targeting 3′ALK and 5′ALK, labeled orange and green, respectively. a. normal nuclei, presenting two 
ALK gene signals; b. nuclei presenting three to four ALK gene signals; c. nuclei presenting three ALK gene 
signals; d. nuclei with amplification of 3’ALK region. 
 
1.1. Clinicopathological characteristics of patient with ALK amplification  
The patient with ALK amplification (81% of the cells) was a female child aged 14 
months old diagnosed with a neuroblastoma (stroma-poor, undifferentiated, low MKI and 
unfavorable histology), located in the right adrenal medulla, with invasion of adjacent 
tissues, regional lymph nodes and the bone marrow. The previous cytogenetic analysis 
showed MYCN amplification in 78% of cells, similar to the ALK pattern found in this study, 
as well as deletion of 1p36 region in 54% of cells. According to INRG risk stratification, the 
tumor was classified as a high-risk neuroblastoma. After neoadjuvant chemotherapy and 
surgery, maturation of tumor cells induced by chemotherapy was observed, being the tumor 
reclassified as a ganglioneuroblastoma, subtype “intermixed” and favorable histology. The 
patient died 12 months after diagnosis.  
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2. ALK mutations in NB patients 
DNA samples from 29 children diagnosed with NB were screened for somatic 
mutations in exons 20 to 28 of the ALK gene by Sanger sequencing. Four different 
mutations were found in five cases, corresponding to a frequency of 17.2% in this cohort. 
Two of these were considered germline mutations, given that they were detected in normal 
tissue (Table IV.2).  
 
Table IV.2: Mutations found in the ALK gene. 
 
 
The mutation found in patients #1 (somatic) and #44 (germline) consists of a 
nonsynonymous substitution of a Guanine for an Adenine (transition, c.3824G>A) at the 
second position of codon 1275 (CGACAA), resulting in a nonconservative substitution of 
an Arginine for a Glutamine, p.(Arg1275Gln) (R1275Q) (Figure IV.2a, b).  
The mutation found in patient #5 (somatic) consists of a nonsynonymous substitution 
of a Cytosine for a Guanine (transversion, c.3522C>G) at the third position of codon 1174 
(TTCTTG), resulting in a nonconservative substitution of an Phenylalanine for a Leucine, 
p.(Phe1174Leu) (F1174L) (Figure IV.2c).  
The mutation found in patient #26 (germline) consists of a nonsynonymous 
substitution of a Guanine for a Cytosine (transversion, c.3575G>C) at the second position 
of codon 1192 (CGGCCG), resulting in a nonconservative substitution of an Arginine for 
a Proline, p.(Arg1192Pro) (R1192P) (Figure IV.2d).  
The mutation found in patient #33 (somatic) consists of a nonsynonymous 
substitution of a Thymine for an Adenine (transversion, c.3520T>A) at the first position of 
codon 1174 (TTCATC), resulting in a nonconservative substitution of an Phenylalanine 
for an Isoleucine, p.(Phe1174Ile) (F1174I) (Figure IV.2e). This mutation has been described 
in sporadic tumors (Carén et al., 2008; Mosse et al., 2008).  
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Figure IV.2: DNA sequence electropherograms obtained from NB tumor samples: a. patient #1: ALK 
c.3824 G>A (reverse strand), p.(Arg1275Gln) (R1275Q); b. patient #44: ALK c.3824 G>A (forward strand), 
p.(Arg1275Gln) (R1275Q) c. patient #5: c.3522C>G (forward strand), p.(Phe1174Leu) (F1174L); d. patient #26: 
c.3575G>C (forward strand), p.(Arg1192Pro) (R1192P); e. patient #33: c.3520T>A (reverse strand), 
p.(Phe1174Ile) (F1174I). 
 
2.1. Clinicopathological characteristics of patients with ALK mutations  
Patient #1, with the somatic ALK mutation c.3824G>A, p.(Arg1275Gln), is a female 
child aged 21 months old diagnosed with a neuroblastoma (stroma-poor, poorly 
differentiated, intermediate MKI, favorable histology), located in the upper mediastinum. 
The tumor presented metastization at supraclavicular ganglia at the time of diagnosis. This 
tumor did not present MYCN amplification or 1p deletion and we did not find ALK 
cytogenetic alterations, however, there was a chromosome 2 polysomy. At the time of 
writing, the patient was under follow-up, with no evidence of disease.  
Patient #5, with the somatic ALK mutation c.3522C>G, p.(Phe1174Leu), is a male 
child aged 20 months old diagnosed with a thoracic ganglioneuroblastoma (stroma-
dominant, favorable histology), with local invasion. The tumor presented deletion of 1p and 
chromosome 2 polysomy. At the time of writing, and after 13 years of follow-up, the patient 
is free of NB, however, he is under treatment for a cervical myxoid liposarcoma diagnosed 
at the age of 13.  
Patient #26, with the germline ALK mutation c.3575G>C, p.(Arg1192Pro), is an eight 
years old female child, diagnosed with a retroperitoneal neuroblastoma (stroma-poor, 
undifferentiated, high MKI and unfavorable histology). The tumor did not present MYCN 
amplification, 1p deletion or ALK cytogenetic alterations. The patient died 28 months after 
diagnosis. There is no history of NB in this family. 
Patient #33, with the somatic ALK mutation c.3520T>A, p.(Phe1174Ile), is a female 
child aged eight months old diagnosed with an abdominal neuroblastoma (stroma-poor, 
undifferentiated, high MKI and unfavorable histology). The tumor did not present MYCN 
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amplification, deletion of 1p and 11q, gain of 17q or ALK cytogenetic alterations. After 
neoadjuvant chemotherapy and surgery, which induced maturation of tumor cells, the tumor 
was reclassified as a neuroblastoma, stroma-poor, differentiating, with low MKI and 
favorable histology. After 20 months of follow-up, a relapse was detected, and classified 
after surgery as a ganglioneuroma, maturing, with low MKI and favorable histology.  
Patient #44, with the germline ALK mutation c.3824G>A, p.(Arg1275Gln), is a 
female child diagnosed at the age 9 months old with an abdominal neuroblastoma, 
presenting metastases in the femur and in the facial bones. The tumor did not present 
MYCN amplification, deletion of 1p or 11q, or gain of 17q. The FISH analysis of ALK was 
not performed in this case. At the present time, the patient is being prepared for an AHSCT. 
Family history is not known at the time of writing.  
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V. DISCUSSION  
 
The discovery of a variety of genetic alterations in tumors leading to oncogenesis 
and the development of target-specific therapies have improving patients’ outcomes in 
different malignancies. Rearrangements, mutations and amplification of the ALK gene have 
been described in a range of tumors, including ALCL, IMT and NSCLC (Hallberg and 
Palmer, 2013). This indicates the ALK protein as a powerful biological marker and a 
therapeutic target in malignancies in which ALK influences carcinogenesis (Bresler et al., 
2011; Solomon et al., 2014). Relatively recent findings have suggested that the ALK gene 
may be activated by amplification or specific mutations targeting the tyrosine kinase domain 
(TKD) in NB patients, presumably contributing to tumor development (Bagci et al., 2012; 
Carén et al., 2008; Chen et al., 2008; George et al., 2008; Janoueix-Lerosey et al., 2008; 
Miyake et al., 2002; Mosse et al., 2008; Osajima-Hakomori et al., 2005; Subramaniam et 
al., 2009). Moreover, germline activating mutations in ALK gene are responsible for more 
than half of NB hereditary cases (Mosse et al., 2008). In the present study, we aimed to 
search for the ALK fusion genes, to compare the patterns of amplification of the ALK and 
MYCN genes, to identify somatic and germline ALK TKD point mutations, and to relate the 
ALK alterations with clinical outcome in NB patients.  
Using the FISH methodology, we searched for ALK chromosome alterations in forty-
one patients from all clinical stages. The ALK gene is involved in the initiation and 
progression of different malignancies, being often activated by translocations (Hallberg and 
Palmer, 2013). In the present study, we did not observe any ALK rearrangement, 
characterized by a split of the ALK probe, suggestive of a translocation or inversion with 
breakpoint within the ALK gene. These rearrangements, although uncommon, have been 
described in previous studies, although in larger cohorts and using more sensitive 
methodologies such as SNP arrays (Cazes et al., 2013; Fransson et al., 2015).  
However, we found cytogenetic aberrations in 46.3% of the cases. Amplification was 
detected in one high-risk NB patient (2.4%), which is in accordance with previous studies 
that report frequencies of 1 to 3% in advanced stages, using FISH (Osajima-Hakomori et 
al., 2005; Subramaniam et al., 2009; Wang et al., 2013) or genome-wide scanning 
approaches (Bagci et al., 2012; Carén et al., 2008; Chen et al., 2008; De Brouwer et al., 
2010; Janoueix-Lerosey et al., 2008; Mosse et al., 2008). This case also presented MYCN 
amplification, which is in agreement with previous studies that suggested the synchronic 
co-amplification of the two genes (Bagci et al., 2012; De Brouwer et al., 2010; George et 
al., 2008; Subramaniam et al., 2009), which is compatible with the similar pattern of 
amplification of both genes in our patient. Although ALK amplification without MYCN 
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amplification is very rare, having only been detected in three cases (Chen et al., 2008; 
Janoueix-Lerosey et al., 2008; Mosse et al., 2008), Chen et al. (2008), showed that 
amplification of ALK and MYCN loci may occur in separated events.  
The copy number gain without amplification was found in our cohort in 31.7% of the 
cases. The ALK copy number gain was described previously in 17 to 45% of the cases, 
being highly associated with more advanced clinical stages and with non-hyperdiploid 
tumors with a worse outcome (Bagci et al., 2012; Carén et al., 2008; Chen et al., 2008; 
Mosse et al., 2008). However, Wang et al. (2013) showed a better outcome of patients with 
ALK copy number gain, which may be related with the fact that the majority of these cases 
also had gain of centromere 2, a feature that suggests a polyploid karyotype that is known 
to confer a favorable prognosis in NB patients. In this cohort, we detected 36.6% of tumors 
with chromosome 2 polysomy, which is an indicator of a better outcome of patients without 
other adverse prognostic features.  
Additionally, we found five cases (12.2%) presenting loss/imbalance of the ALK 
locus, characterized by increased centromere of chromosome 2 probe signals, and lower 
number of the ALK gene signals. This cytogenetic category was reported for the first time 
by Subramaniam et al. (2009). Four of five cases with ALK loss/imbalance also showed 
MYCN loss/imbalance. This can be explained by gain of a rearranged chromosome 2 with 
relative ALK and MYCN allelic loss (Subramaniam et al., 2009). Interestingly, neither 
deletion of 1p and 11q or duplication of 17q showed correlation with ALK copy number 
alterations, which is in agreement with the results showed by Subramaniam et al. (2009).  
In this study, we searched for ALK mutations in twenty-nine NB tumors by Sanger 
sequencing and we found a frequency of 17.2%, which is higher when compared to previous 
studies that described frequencies of 7 to 14% (Azarova et al., 2011). Four of the five ALK 
mutations identified occurred at positions R1275 and F1174, which are two mutational 
hotspots in sporadic tumors. A meta-analysis of 709 NB tumors identified these mutations 
in tumors of all clinical stages and genomic profiles, in 49% and 34.7% of sporadic NB, 
respectively. However, they described a significantly higher frequency of F1174 mutations 
in MYCN-amplified tumors, which might explain the inferior survival reported by them in 
these patients. Additionally, Schonherr et al. (2012) proposed that MYCN may cooperate 
with ALK activating mutations to increase cell transformation and synergistically contribute 
to tumor development, since the ALK gene is a direct transcriptional target of MYCN and a 
downregulation or inhibition of ALK results in a decreased MYCN expression (Hasan et al., 
2013; Schonherr et al., 2012). In the present study, we did not find any ALK mutations in 
any of MYCN amplified cases, which may be due the small number of cases analyzed. 
The mutation R1275Q found in two of five cases was previously described in several 
studies as one of the most frequent mutations occurring in both sporadic (Carén et al., 2008; 
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Chen et al., 2008; De Brouwer et al., 2010; George et al., 2008; Janoueix-Lerosey et al., 
2008; Mosse et al., 2008) and hereditary NB cases (Janoueix-Lerosey et al., 2008; Mosse 
et al., 2008). This mutation has been associated with higher autophosphorylation and 
phosphorylation of downstream targets, such as ERK1/2 and Akt with high capacity of 
transformation in NIH 3T3 and Ba/F3 assays (Chen et al., 2008; De Brouwer et al., 2010; 
George et al., 2008). Studies performed by Ueda et al. (2016), demonstrated that the 
mutation R1275Q alone was not sufficient to tumor development in mice, but NB 
development occurred when the mutation was concurrent with MYCN expression. They 
suggested that this activating mutation contribute to the pathogenicity of NB by 
downregulation of the expression of extracellular matrix (ECM)- and basement membrane 
(BM)- associated genes, enhancing the ability of tumor MYCN-expressing cells to migrate 
and invade. Furthermore, the ALK-inhibitor agent-crizotinib showed almost completely 
suppression of ALK R1275Q mutated tumors growth in xenograft models (Bresler et al., 
2011; Ueda et al., 2016).  
The mutation F1174L found in one of five patients has been almost exclusively 
detected in sporadic tumors (Carén et al., 2008; Chen et al., 2008; George et al., 2008; 
Janoueix-Lerosey et al., 2008; Mosse et al., 2008; Okubo et al., 2012), probably reflecting 
the higher kinase activity and cell transforming capacity of this mutation. The F1174L 
mutation shows a high degree of autophosphorylation and phosphorylation of downstream 
targets involved in PI3K/Akt/mTOR and MAPK signal transduction pathways, and is 
preferentially associated with MYCN amplified cases (Berry et al., 2012; Chen et al., 2008; 
De Brouwer et al., 2010; George et al., 2008). Berry et al. (2012) demonstrated that this 
mutation did not induce tumor development by itself, however, it potentiates the oncogenic 
effects of MYCN, contributing to its stabilization and, consequently, to the development of 
more aggressive tumors. Studies in cell lines have showed that this mutation is extremely 
sensitive to the potent ALK inhibitor TAE684 (George et al., 2008) whereas it seems to be 
predictive of resistance to crizotinib (Bresler et al., 2011). Berry and colleagues associated 
this resistance with the incomplete inhibition of the key signaling cascades induced by 
F1174L mutation. Treatment with crizotinib leads to reduction of pALK and pAkt levels, 
however, it lacks any effect in pERK or activated mTOR signaling. Therefore, patients 
carrying the F1174L mutation may benefit from a combined therapy with crizotinib and 
torin2, an ATP-competitive inhibitor of mTOR (Berry et al., 2012).  
The mutation F1174I found in one of five tumors is located at the same position as 
the F1174L mutation, however, it has been described less frequently (Berry et al., 2012; 
Carén et al., 2008; Mosse et al., 2008). Similarly to ALK F1174L, this mutation is expected 
to be pathogenic, however, no functional studies have been performed for this specific 
mutation.  
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In this study, we identified two germline mutations, the R1275Q and the R1192P 
initially identified in the tumor and subsequently confirmed to be present also in the 
germline. The germline R1275Q mutation is the most frequent mutation described in 
hereditary NB (Bourdeaut et al., 2012; George et al., 2008; Janoueix-Lerosey et al., 2008; 
Mosse et al., 2008). Mosse et. al. (2008) who studied 20 NB families, found the R1275Q 
ALK mutation in five of eight families with ALK germline mutations. Furthermore, all families 
with this mutation showed at least two affected first-degree individuals, although several 
asymptomatic carriers were also identified, suggesting incomplete penetrance (Janoueix-
Lerosey et al., 2008; Mosse et al., 2008). The patient with the R1275Q germline mutation 
detected in the present work was diagnosed at the age of nine months old, with metastatic 
disease, which is suggestive of hereditary NB.  
The germline R1192P mutation found in one case has only been described in 
hereditary NB cases, being the second commonest germline mutation detected in NB 
patients. The mutation was previously detected in two of the eight families found with ALK 
germline mutations by Mosse and colleagues (Mosse et al., 2008). Interestingly, this 
mutation was always inherited from an unaffected parent, and the age at diagnosis ranged 
from three months to 12 years (Bourdeaut et al., 2012; Janoueix-Lerosey et al., 2008; 
Mosse et al., 2008). The patient carrying the R1192P germline mutation in the present 
cohort was diagnosed at the age of eight years old, with an unfavorable tumor. Additionally, 
to our knowledge there is no history of NB in this family. However, given the possibility of 
incomplete penetrance, we cannot exclude the existence of unaffected carriers in this 
family. Moreover, cases have been described of unaffected carriers that had spontaneously 
regressive tumors or asymptomatic stroma-rich tumors (Bourdeaut et al., 2012).  
Concluding, ALK alterations are a frequent event in NB patients, either by 
cytogenetic events or point mutations, being a potential clinically useful predictive and 
prognostic biomarker that may be a therapeutic target in a subset of patients. The results 
obtained in this work suggest the need of new molecular diagnostic recommendations for 
NB patients, which will allow the clinical evaluation of ALK inhibitors. However, further 
studies are needed to identify which patients are more likely to respond to ALK inhibitors. 
Additionally, we also found two children with germline ALK mutations, which can help direct 
screening of healthy relatives with NB predisposition and of second primary in the patients, 
although further studies are necessary to establish the penetrance of the various germline 
mutations. 
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VI. FUTURE PERSPECTIVES 
 
This study may benefit from further analysis to support our conclusions and to allow 
a more complete characterization of the ALK gene in NB patients. Thus, we plan: 
 
➢ To increase our cohort to 56 NB patients; 
➢ To analyze by FISH and Sanger sequencing formalin fixed paraffin 
embedded tissue from the remaining cases;  
➢ To evaluate the ALK expression pattern by immunohistochemistry (IHC) in 
all cases, to compare the protein expression between ALK altered and 
normal cases. 
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Supplementary Table  1: The International Neuroblastoma Pathology Classification 
(Shimada system) [adapted from (Shimada et al., 1999)]. 
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Supplementary Table  2: International Neuroblastoma staging system (Brodeur, et al. 
1993). 
 
 
 
   
 
 
 
  
   
 
 
 
 
